ALNY vs. ICLR: Alnylam Pharmaceuticals vs. ICON Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and ICON (ICLR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and ICON (ICLR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while ICLR is classified in Life Sciences Tools & Services.
| Profile Item | ALNY | ICLR |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | ICON plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 20.89 billion USD | 15.34 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | May 15, 1998 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | ICLR |
|---|---|---|
| Total Return (1Y) | -64.57% | 30.55% |
| Total Return (3Y, Annualized) | -1.58% | -6.05% |
| Total Return (5Y, Annualized) | -3.13% | -5.40% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | ICLR |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 68.62% |
| Beta (5Y) | 0.45 | 1.17 |
| Max Drawdown (5Y) | -68.25% | -76.87% |
| Avg. Volume (3M) | 1.90M | 943.50K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | ICLR |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.38 |
| Sortino Ratio (1Y) | -1.45 | 0.52 |
Profitability
ROE (TTM)
Alnylam Pharmaceuticals (ALNY) at 138.07% clears its industry range for ROE, a sharper capital-efficiency signal than ICON (ICLR) at 4.70%, which is closer to a typical peer reading.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70%
- Max
- 109.18%
- Q3
- 6.23%
- ICLR
- 4.70%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and ICON (ICLR) at 5.26% also retains a top-quartile share.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.26%
- Max
- 18.05%
- ICLR
- 5.26%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.73%
- Max
- 83.12%
- Q3
- 14.77%
- ICLR
- 10.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | ICLR |
|---|---|---|
| ROE (TTM) | 138.07% | 4.70% |
| ROA (TTM) | 9.51% | 0.85% |
| Net Margin (TTM) | 52.85% | 5.26% |
| Operating Margin (TTM) | 23.72% | 10.73% |
| Gross Margin (TTM) | 77.28% | 23.44% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while ICON (ICLR) at 0.76% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | ICLR |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 0.76% |
| Revenue Growth (3Y CAGR) | 52.98% | 2.15% |
| EPS Growth (YoY) | -- | -71.56% |
| EPS Growth (3Y CAGR) | -- | -23.82% |
Financial Strength
Current Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.32
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ICLR
- 1.32
- Min
- 0.10
Debt / Equity (MRQ)
ICON (ICLR) at 0.38 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- ICLR
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | ICLR |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 1.32 |
| Debt / Equity (MRQ) | 0.83 | 0.38 |
| Net Debt / EBITDA | -0.57 | 5.55 |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | ICLR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while ICON (ICLR) at 81.90 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.90
- Max
- 85.34
- ICLR
- 81.90
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Alnylam Pharmaceuticals (ALNY) at 4.17 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.86
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ICLR
- 1.86
- Min
- 0.01
P/B Ratio (MRQ)
ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile against book while Alnylam Pharmaceuticals (ALNY) at 5.79 is valued near its industry’s middle — ICLR is cheaper on assets, though weigh it against ROE and asset quality.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.68
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- ICLR
- 1.68
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | ICLR |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 81.90 |
| P/S Ratio (TTM) | 4.17 | 1.86 |
| P/B Ratio (MRQ) | 5.79 | 1.68 |
| Free Cash Flow Yield (TTM) | 1.57% | 3.51% |